DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...
Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Vancouver, BC, Canada, January 26th...
Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...
DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...
VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS Vancouver, BC, Canada, November...
DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER Vancouver, BC, Canada, October 13th...
DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...
DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...
DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS Vancouver, BC, Canada, September 20th, 2021 -- InvestorsHub NewsWire -- Defence...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 1.88679245283 | 0.53 | 0.66 | 0.48 | 28747 | 0.60785952 | CS |
4 | -0.08 | -12.9032258065 | 0.62 | 0.66 | 0.48 | 33748 | 0.56890888 | CS |
12 | -0.26 | -32.5 | 0.8 | 0.96 | 0.48 | 36282 | 0.70729147 | CS |
26 | -1.16 | -68.2352941176 | 1.7 | 1.92 | 0.48 | 37892 | 1.00654699 | CS |
52 | -2.16 | -80 | 2.7 | 3.01 | 0.48 | 28281 | 1.43285758 | CS |
156 | -6.46 | -92.2857142857 | 7 | 7.1 | 0.48 | 18401 | 2.43125495 | CS |
260 | -1.21 | -69.1428571429 | 1.75 | 8.15 | 0.48 | 18183 | 2.73751471 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.